This study aimed to undertaken to design and evaluate solid lipid nanoparticles (SLNs) containing dapagliflozin in order to improve its oral absorption and provide prolonged drug delivery for Type 2 Diabetes Mellitus (T2DM) therapy. A Box–Behnken experimental approach guided the optimization process. The final formulation demonstrated desirable characteristics, including a mean particle size of 116.4 ± 2.3 nm, a PDI of 0.24, surface charge of –33.3 mV, and entrapment efficiency of 81.0 ± 1.8%.Thermal and structural studies using DSC, PXRD, and FTIR confirmed both the conversion of dapagliflozin from crystalline to amorphous form and its successful incorporation into the lipid carrier. Dissolution testing showed a two-phase release profile: roughly one-quarter of the drug released within the first 2 hours, followed by a controlled release extending up to 24 hours, with a cumulative release of about 91.2%. Drug release data fitted best to the Korsmeyer–Peppas model (R² = 0.981), indicating an anomalous, non-Fickian release mechanism. Stability testing conducted for six months under ICH-recommended storage conditions revealed minimal deviations in particle size, entrapment efficiency, and drug assay, verifying the formulation’s robustness and shelf-life potential.